Company
Immutep Limited
ASX:IMM
Immutep develops immunotherapies built around LAG-3, an immune checkpoint protein that regulates T-cell activity. Its portfolio runs in two directions from the same biology: agonist-style candidates (led by eftilagimod alfa, a soluble LAG-3 protein) intended to stimulate antigen-presenting cells and T-cells against tumours, and antagonist candidates intended to damp down T-cell activity in autoimmune disease. That two-sided position on T-cell regulation is what makes it relevant to the immune-ageing (immunosenescence) axis rather than to a single tumour type. It is not a geroscience company and does not run ageing-endpoint trials; the longevity link is mechanistic, via immune regulation, not by stated intent. Inclusion is on both limbs of the rule: ASX-listed and Sydney-headquartered. The honest negative: its most advanced oncology programme failed a Phase III interim futility analysis in March 2026, so the near-term clinical case rests on the remaining earlier-stage assets.
At a glance
- Listing
- ASX:IMM
- Category
- ASX listed
- Headquarters
- Sydney, New South Wales, Australia
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- ASX listed
- Market
- Australia
- Recent inflection
- 13 March 2026: the Independent Data Monitoring Committee recommended discontinuing the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small cell lung cancer following a planned interim futility analysis. Enrolment was halted and the study wound down. The company said its cash runway would extend well beyond the previously guided Q2 CY2027, without giving a revised figure at the time. Immutep's Nasdaq ADRs fell from US$2.76 to US$0.48 on the announcement, about 83 percent. Source: GlobeNewswire company release, 13 March 2026.
- Services
- None recorded
- People tracked
- 1
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:IMM |
| Secondary listing | NASDAQ |
| Market cap | Not disclosed |
| Status | Listed and trading |
Get in touch
Contact
- Address
- Sydney, New South Wales, Australia
- Website
- www.immutep.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
People
Who variis tracks here (1)
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
What moved lately
13 March 2026: the Independent Data Monitoring Committee recommended discontinuing the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small cell lung cancer following a planned interim futility analysis. Enrolment was halted and the study wound down. The company said its cash runway would extend well beyond the previously guided Q2 CY2027, without giving a revised figure at the time. Immutep's Nasdaq ADRs fell from US$2.76 to US$0.48 on the announcement, about 83 percent. Source: GlobeNewswire company release, 13 March 2026.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Immutep: LAG-3 immunotherapy, four clinical-stage assets in oncology and autoimmune disease; HQ Level 32, Australia Square, 264 George Street, Sydney NSW 2000 · Immutep Limited
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis · GlobeNewswire (Immutep Limited release, 13 March 2026)
- Immutep hit with securities suit after TACTI-004 trial halt and 83% stock drop · TipRanks
Every entity profile on variis is sourced. Not investment advice.